Understanding CKD and SGLT2-inhibition: What are the key mechanisms?
Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.
Video navigation menu
- Consequences of diabetic kidney disease 00:53
- Effect of SGLT2 inhibition on renal outcomes 02:12
- Why does SGLT2 inhibition work so well? 04:16
- The 'tubular hypothesis' of SGLT2 inhibition 05:26
- Personal view on how SGLT2 inhibitors work 07:18
This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.
Professor Per-Henrik Groop, MD is currently Professor of Internal Medicine (Chair) at the University of Helsinki. He is also Chief Physician at the Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital and Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland. He is also Professor at the Baker Heart and Diabetes Institute in Melbourne, Australia.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.